König, Alexander Otto

[["dc.bibliographiccitation.firstpage","1280"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Theranostics"],["dc.bibliographiccitation.lastpage","1287"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Berger, Andreas W."],["dc.contributor.author","Schwerdel, Daniel"],["dc.contributor.author","Reinacher-Schick, Anke"],["dc.contributor.author","Uhl, Waldemar"],["dc.contributor.author","Algül, Hana"],["dc.contributor.author","Friess, Helmut"],["dc.contributor.author","Janssen, Klaus-Peter"],["dc.contributor.author","König, Alexander"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Gallmeier, Eike"],["dc.contributor.author","Bartsch, Detlef K."],["dc.contributor.author","Geissler, Michael"],["dc.contributor.author","Staib, Ludger"],["dc.contributor.author","Tannapfel, Andrea"],["dc.contributor.author","Kleger, Alexander"],["dc.contributor.author","Beutel, Alica"],["dc.contributor.author","Schulte, Lucas-Alexander"],["dc.contributor.author","Kornmann, Marko"],["dc.contributor.author","Ettrich, Thomas J."],["dc.contributor.author","Seufferlein, Thomas"],["dc.date.accessioned","2019-07-09T11:50:26Z"],["dc.date.available","2019-07-09T11:50:26Z"],["dc.date.issued","2019"],["dc.description.abstract","The most frequent malignancy of the pancreas is the pancreatic ductal adenocarcinoma (PDAC). Despite many efforts PDAC has still a dismal prognosis. Biomarkers for early disease stage diagnosis as a prerequisite for a potentially curative treatment are still missing. Novel blood-based markers may help to overcome this limitation. Methods: Prior to surgery plasma levels of thrombospondin-2 (THBS2), which was recently published as a novel biomarker, and CA19-9 from 52 patients with histologically proven PDAC were determined, circulating cell-free (cfDNA) was quantified. 15 patients with side-branch IPMNs without worrisome features and 32 patients with chronic pancreatitis served for comparison. Logit (logistic regression) models were used to test the performance of single biomarkers and biomarker combinations. Results: CA19-9 and THBS2 alone showed comparable c-statistics of 0.80 and 0.73, respectively, improving to 0.87 when combining these two markers. The c-statistic was further increased to 0.94 when combining CA19-9 and THBS2 with cfDNA quantification. This marker combination performed best for all PDAC stages but also for PDACs grouped by stage. The greatest improvement over CA19-9 was seen in the group of stage I PDAC, from 0.69 to 0.90 for the three marker combination. Conclusion:These data establish the combination of CA19-9, THBS2 and cfDNA as a composite liquid biomarker for non-invasive diagnosis of early-stage PDAC."],["dc.identifier.doi","10.7150/thno.29247"],["dc.identifier.pmid","30867830"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15940"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59773"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1838-7640"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.subject.ddc","610"],["dc.title","A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","1206"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Krug, Sebastian"],["dc.contributor.author","Kegel, Thomas"],["dc.contributor.author","Gress, Thomas M."],["dc.contributor.author","Rinke, Anja"],["dc.contributor.author","Apostolidis, Leonidas"],["dc.contributor.author","Jann, Henning"],["dc.contributor.author","König, Alexander"],["dc.contributor.author","Hörsch, Dieter"],["dc.contributor.author","Schrader, Jörg"],["dc.contributor.author","Ettrich, Thomas J."],["dc.contributor.author","Richter, Michael"],["dc.contributor.author","Steighardt, Jörg"],["dc.contributor.author","Michl, Patrick"],["dc.date.accessioned","2021-11-25T11:00:15Z"],["dc.date.accessioned","2022-08-18T12:35:02Z"],["dc.date.available","2021-11-25T11:00:15Z"],["dc.date.available","2022-08-18T12:35:02Z"],["dc.date.issued","2021-11-12"],["dc.date.updated","2022-07-29T12:07:14Z"],["dc.description.abstract","Abstract\r\n \r\n Background\r\n Cytotoxic chemotherapy combinations and targeted agents represent established treatment concepts in advanced pancreatic neuroendocrine tumors (PNETs). However, response rates, side effects and outcome data strongly vary among these therapeutic approaches. Head-to-head comparisons between chemo- and molecular therapies are missing and secondary resistances frequently occur. The RamuNET trial aims to identify the effectiveness of dual treatment with DTIC and ramucirumab in progressive advanced PNET patients.\r\n \r\n \r\n Methods\r\n The RamuNET study is an investigator-initiated multicenter prospective single-arm trial to evaluate the efficacy of ramucirumab in combination with dacarbazine (DTIC) over a period of at least 6 months. Patients with progressive well-differentiated and metastatic pancreatic neuroendocrine tumors are eligible. The study aims to include 45 patients over a period of 24 months with a minimum follow-up of 24 months. The primary endpoint is disease control after 6 months. Secondary endpoints include progression-free survival, biochemical response, overall survival, quality of life and toxicity. Based on the hypothesis that 80% of the patients can achieve a disease control after 6 months, the sample size calculation follows an exact binomial single-stage design. H0: p < =p0 = 60% versus H1: p > =p1 = 80%, alpha = 0.05, beta = 0.1.\r\n \r\n \r\n Discussion\r\n This study investigates a new therapeutic approach using the combination of cytotoxic and targeted antiangiogenic therapy in advanced PNET. If positive, this trial will be the basis for a randomized two-arm study to investigate the combination of ramucirumab and DTIC against other established therapies in PNET.\r\n \r\n \r\n Trial registration\r\n \r\n EudraCT: 2017–001207-68\r\n \r\n . Date of registration: 2018.01.03."],["dc.identifier.citation","BMC Cancer. 2021 Nov 12;21(1):1206"],["dc.identifier.doi","10.1186/s12885-021-08900-7"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/93519"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112936"],["dc.language.iso","en"],["dc.publisher","BioMed Central"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)"],["dc.subject","PanNET"],["dc.subject","PNET"],["dc.subject","Chemotherapy"],["dc.subject","Ramucirumab"],["dc.subject","DTIC"],["dc.subject","Neuroendocrine"],["dc.title","Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]